A better understanding of how serotonin, a neurotransmitter which helps brain cells communicate with one another, could lead to a radical shift in psychiatric care, according to a new paper.
Despite its importance, current models to explain serotonin’s function in stabilising mood and regulating stress remain incomplete.
Now, in a review paper published this month in the Journal of Psychopharmacology, researchers from Imperial College London suggest that serotonin pathways are more nuanced than previously thought.
They argue that the existing view should be updated to incorporate a ‘two-pronged’ model of how serotonin acts.
The researchers believe their updated model could have implications for treating recalcitrant mental health conditions, including depression, obsessive compulsive disorder and addiction, and could exploit the therapeutic potential of psychedelic drugs.
In the brain, serotonin acts via a number of sites called ‘receptors’ and serotonin has at least 14 of these. Brain drugs such antidepressants, antipsychotics and psychedelics are known to interact with serotonin receptors and two of these are thought to be particularly important - the so-called serotonin 1A and 2A receptors.
For patients with depression, commonly prescribed drugs called SSRIs (Selective Serotonin Reuptake Inhibitors) can help to relieve symptoms by boosting levels of serotonin in the brain. Evidence suggests an important part of how they work is to increase activity at the serotonin 1A receptor, which reduces brain activity in important stress circuitry, thereby helping a person cope better.
In contrast, psychedelic compounds such as LSD and psilocybin (the psychoactive component of magic mushrooms), are thought to act primarily on the serotonin 2A receptor. Accumulating evidence suggests that psychedelics with psychotherapy can be an effective treatment for certain mental illnesses and, with a focus on the 2A receptor, the authors’ paper attempts to explain why.
“We may have got it wrong in the past,” said Dr Robin Carhart-Harris, Head of Psychedelic Research at Imperial and lead author on the paper. “Activating serotonin 2A receptors may be a good thing, as it makes individuals very sensitive to context and to their environment. Crucially, if that is made therapeutic, then the combination can be very effective. This is how psychedelics work – they make people sensitive to context and ‘open’ to change via activating the 2A receptor.”
According to the researchers, the 1A and 2A pathways form part of a two-pronged approach which may have evolved to help us adapt to adversity. By triggering the 1A pathway, serotonin can make situations less stressful, helping us to become more resilient. However, they argue that this approach may not always be enough, and that in extreme crises, the 2A pathway may kick in to rapidly open a window of plasticity in which fundamental changes in outlook and behaviour can occur.